PIK3CA mutations in human solid tumors: Role in sensitivity to various therapeutic approaches
Giovanni Ligresti(Boston University), Massimo Libra(University of Catania), James A. McCubrey(East Carolina University), A Cavallaro(University of Catania), Ferdinando Nicoletti(University of Catania), Francesco Basile(Nurix (United States)), Franca Stivala(University of Catania), Linda S. Steelman(East Carolina University), Loredana Militello(University of Catania)
Cited by 213
Related Papers
Natural products in drug discovery: advances and opportunities
|Nature Reviews Drug Discovery|2021|5.2k
Evolution of Cancer Pharmacological Treatments at the Turn of the Third Millennium
|Frontiers in Pharmacology|2018|878
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health
|Oncotarget|2011|579
GSK-3 as potential target for therapeutic intervention in cancer
|Oncotarget|2014|508